We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
UK drug industry association ABPI has published a report hailing
the pharmaceutical industry's role in developing new compounds to treat key
cancers, in particular breast cancer.
A report by the Federation of India Chambers of Commerce and Industry (FICCI)
has called for the liberalisation of pricing controls in the pharmaceutical
sector, coupled with increased investment in R&D.
Tioga Pharmaceuticals has been formed to develop a medicine (asimadoline) to
treat pain in irritable bowel syndrome (IBS) patients and other gastrointestinal
diseases.
Codexis, a privately-held biosciences company, announced it has signed an agreement
with Matrix Laboratories (Matrix), a leading provider of active pharmaceutical
ingredients (APIs) to the global pharmaceutical industry, for the development
and commercialization of the API for a high-value pharmaceutical product.
Napo Pharmaceuticals announced that it has granted AsiaPharm Group an exclusive
license to develop and commercialize for China (including Hong Kong and Macau)
products derived from crofelemer to treat chronic diarrhea in people living
with HIV/AIDS (AIDS-related diarrhea), acute infectious diarrhea and pediatric
diarrhea.
A cautious pricing strategy paid off for TopoTarget A/S, as its initial public
offering of 10 million shares on the Copenhagen Stock Exchange, which yielded
gross proceeds of DKK225 million (US$36.5 million), was more than six times
over-subscribed.
Despite the fact that HIV/AIDS drug nevirapine - developed
by Germany's Boehringer Ingelheim - was a major component of South Africa's
recent ARVs tender, there is evidence that sufferers are failing to take up
the drug in sufficient numbers.